The human retinoblastoma susceptibility gene (RB1): an evolutionary story in primates.

Mamm Genome

Genetics Program, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 20231-050, Rio de Janeiro, RJ, Brazil.

Published: June 2017

AI Article Synopsis

  • The RB1 gene is crucial for normal cellular functions and is a key factor in the development of retinoblastoma, a type of eye cancer.
  • Comparisons of the RB1 gene in humans and 19 non-human primates revealed many nucleotide changes, leading to significant amino acid variations in the gene's protein product.
  • While some alterations found in non-human primates are similar to those linked to retinoblastoma in humans, they do not seem to cause any health issues in those species.

Article Abstract

The tumor suppressor gene RB1 (Human Retinoblastoma Susceptibility Gene) plays a prominent role in normal development, gene transcription, DNA replication, repair, and mitosis. Its complete biallelic dysfunction in retinoblasts is the main cause of retinoblastoma in the human. Although this gene has been evolutionary conserved, comparisons between the reference and human RB1 coding region with its counterparts in 19 non-human primates showed 359 sites where nucleotide replacements took place during the radiation of these species. These resulted in missense substitutions in 97 codons, 91 of which by amino acids with radically different physicochemical properties. Several in frame deletions and two insertions were also observed in the N-terminal region of the pRB protein where the highest number of amino acid substitutions and radical amino changes were found. Fifty-six codons were inferred to be under negative selection and five under positive selection. Differences in codon usage showed evident phylogenetic signals, with hominids generally presenting higher indices of codon bias than other catarrhines. The lineage leading to platyrrhines and, within platyrrhines, the lineage leading to Saimiri boliviensis showed a high rate of nucleotide substitutions and amino acids. Finally, several RB1 alterations associated to retinoblastoma in the human were present in several non-human primates without an apparent pathological effect.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00335-017-9689-4DOI Listing

Publication Analysis

Top Keywords

human retinoblastoma
8
retinoblastoma susceptibility
8
susceptibility gene
8
gene rb1
8
retinoblastoma human
8
non-human primates
8
amino acids
8
lineage leading
8
human
5
gene
5

Similar Publications

Introduction: This study aimed to evaluate the imaging findings of the chest flat panel detector computed tomography (FDCT) among coronavirus disease-2019 (COVID-19) positive patients during urgent/emergent interventional neuroradiologic procedures.

Materials And Methods: Chest FDCT examinations were performed using a C-arm mounted FDCT within the interventional radiology (IR) suite if the reverse transcription polymerase chain reaction (RT-PCR) results were pending in patients with clinical findings suggestive of COVID-19. In those who already had positive RT-PCR results, FDCT was performed for acute evaluation only if an acute unexpected cardiopulmonary event occurred during the procedure.

View Article and Find Full Text PDF

Prognostic Value of Retinoblastoma in Small Intestinal Adenocarcinoma: A Multicenter Retrospective Study.

J Korean Med Sci

December 2024

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: The retinoblastoma (RB) protein which is encoded by gene selectively provides a cell type-specific function in malignancies. In colorectal carcinoma, RB has been highly expressed and related cyclin/cyclin-dependent kinase 4/6 inhibitors have shown improved therapeutic effects in some patients. However, little is known about RB in small intestinal adenocarcinoma (SIAC).

View Article and Find Full Text PDF

Background: To describe the spectrum, demographic profile and distribution of intraocular oncology cases; both benign and malignant, in pediatric population in India.

Methods: It was a retrospective study done at a tertiary care hospital over a period of seven years (January 2015- December 2022) which included all the children aged 0-16 years, clinically diagnosed as intraocular tumors (benign or malignant) referred to our Ocular Oncology clinic. The data was retrieved from medical records department as well as electronic medical system (EMR) system.

View Article and Find Full Text PDF

Retinoblastoma, a rare childhood eye cancer, has hereditary and non-hereditary forms. While TNM classification helps in prognosis, understanding molecular mechanisms is vital for the clinical behavior of retinoblastoma prediction. Our study aimed to analyze the expression levels of key Wnt pathway proteins, GSK3β, LEF1, β-catenin, and DVL1, and associate them to non-phosphorylated active form (pRb) and the phosphorylated inactive form (ppRb) and N-myc expression, in retinoblastoma cells and healthy retinal cells, in order to elucidate their roles in retinoblastoma and identify potential targets that could help to improve diagnostic and therapy.

View Article and Find Full Text PDF

Global, regional and national burden due to retinoblastoma in children aged younger than 10 years from 1990 to 2021.

BMC Med

December 2024

Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

Background: Retinoblastoma (RB), an aggressive intraocular malignancy, significantly adds to the global disease burden in early childhood. This study offers insights into the global burden of retinoblastoma (RB) in children aged 0-9 years, examining incidence, mortality, and DALYs from 1990 to 2021, across age, sex, location, and SDI levels. It aims to inform health policy, resource allocation, and RB combat strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!